Clinical Trials Sponsored by Eisai Korea Inc.

Total 857 results

Eisai Inc.

Completed

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Canada, France, Italy, Korea, Republic of, Spain, United States, Belgium, Czechia, Hungary, Japan, Latvia, Poland
Eisai Inc.

Completed

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Ewing Sarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma | Relapsed/Refractory Rhabdomyosarcoma

United States
Eisai Inc.

Completed

Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States, Spain, France, Germany, Italy, Japan, United Kingdom
Eisai Inc.

Completed

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

Liver Cancer

France
Eisai Inc.

Completed

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Eisai Inc.

Completed

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

Postoperative Nausea and Vomiting

United States
Eisai Inc.

Terminated

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

Photosensitive Epilepsy

United States
Eisai Inc.

Completed

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Thyroid Cancer

United States, Australia, France, Poland, United Kingdom, Italy
Eisai Inc.

Terminated

Study of E7046 in Subjects With Selected Advanced Malignancies

Tumors

United States, France
Eisai Inc.

Completed

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) (SUNRISE 1)

Insomnia

United States, Spain, United Kingdom, Italy, Germany, France, Canada
Eisai Inc.

Completed

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Insomnia

United States
Eisai Inc.

Completed

A Food-Effect Study of E7386 in Healthy Participants

Food Effect in Healthy Participants

United States
Eisai Inc.

Completed

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Stage IV Melanoma | Unresectable Stage III

United States, United Kingdom, Australia, Germany
Eisai Inc.

Completed

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Obesity

United States
Eisai Inc.

Completed

Safety and Efficacy of APD356 in the Treatment of Obesity

Obesity

United States
Eisai Inc.

Completed

Safety and Efficacy of APD356 in the Treatment of Obesity

Obesity

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Eisai Inc.

Completed

Trial of Decitabine in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Poland, Australia, Spain, France, Canada, Mexico, Romania, Taiwan, Russian Federation, Hungary, Serbia, Croatia, United Kingdom, Czechia
Eisai Inc.

Completed

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

HER2-normal

United States
Eisai Inc.

Completed

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Lennox-Gastaut Syndrome

France, Poland, United States, South Africa, Italy, Canada, Greece
Eisai Inc.

Completed

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

Epilepsy

United States, Poland, Belgium, India, Korea, Republic of, Thailand, Hungary, Latvia, Czechia, Australia, Spain
Eisai Inc.

Completed

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Epilepsy

United States
Eisai Inc.

Completed

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Metastatic Renal Cell Carcinoma

United States, Poland, United Kingdom, Spain, Czechia
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

Breast Cancer

United States
Eisai Inc.

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730

Healthy Participants

United States
Eisai Inc.

Completed

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Thrombocytopenia Associated With Liver Disease

United States, Italy, China, Taiwan, Spain, Belgium, Poland, Portugal, Canada, Korea, Republic of, Australia, Brazil, Chile, Austria, Germany, Hungary, France, Argentina, United Kingdom, Thailand
Eisai Inc.

Completed

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Thrombocytopenia

United States
Eisai Inc.

Terminated

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Idiopathic Thrombocytopenic Purpura

United States
Eisai Inc.

Completed

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

Thrombocytopenia Related to Chronic Liver Disease

United States
Eisai Inc.

Withdrawn

A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

Vertigo

China
Eisai Inc.

Completed

Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects

Healthy Participants

United States
Eisai Inc.

Terminated

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Unresectable Stage III Melanoma | Wild Type BRAF Stage IV Melanoma

United States
Eisai Inc.

Completed

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

Unspecified Adult Solid Tumor, Protocol Specific

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Eisai Inc.

Completed

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Epilepsy

Belgium, Germany, China, Hong Kong, United States, France, Romania, Mexico, South Africa, India, Portugal, Russian Federation, Italy, Canada, Australia, Taiwan, Austria, Malaysia, Hungary, Poland, Thailand, Sweden, Bulgaria, Serbia, Greece and more
Eisai Inc.

Completed

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Eisai Inc.

Completed

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

Acute Coronary Syndrome

United Kingdom, United States
Eisai Inc.

Completed

A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

Cancer

United Kingdom
Eisai Inc.

Completed

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Solid Tumors

United States
Eisai Inc.

Completed

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

Hong Kong, Italy, Australia, Spain, Portugal, Taiwan, India, Thailand, Hungary, Poland, Bulgaria, Serbia, Russian Federation, Korea, Republic of, Ukraine, Romania, Latvia, Lithuania, Germany, Estonia, Czech Republic, Philippines, Ma...
Eisai Inc.

Completed

A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

Epilepsy

Australia, France, Poland, Germany, Spain, India, Serbia, Greece, Korea, Republic of, Russian Federation, Taiwan, Hungary, Italy, Sweden, Denmark, Slovakia, United Kingdom, South Africa
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Canada, Chile, Hungary, Bulgaria, Estonia, Latvia, United States, Croatia, Australia, India, Argentina, France, Germany
Eisai Inc.

Completed

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Epilepsy

United States
Eisai Inc.

Completed

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

Healthy Subjects

United States
Eisai Inc.

Completed

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

Metabolism and Excretion

United States
Eisai Inc.

Completed

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects

Healthy Subjects
Eisai Inc.

Completed

Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia

Parkinson's Disease | Dementia

United Kingdom
Eisai Inc.

Completed

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

Cancer, Malignant Tumors

United States
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States

3

Subscribe